Page 19 - Read Online

Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 T, Caramella C, Schlumberger M, Planchard D, Elias D, Ducreux M,
in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Scoazec JY, Baudin E. Are G3 ENETS neuroendocrine neoplasms
Study Group. Everolimus for the treatment of advanced, non- heterogeneous? Endocr Relat Cancer 2013;20:649-57.
functional neuroendocrine tumours of the lung or gastrointestinal 31. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund
tract (RADIANT-4): a randomised, placebo-controlled, phase 3 P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E,
study. Lancet 2016;387:968-77. Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH,
27. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard- Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and
Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch prognostic factors for treatment and survival in 305 patients with
D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, advanced gastrointestinal poorly differentiated neuroendocrine
Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for carcinoma: the NORDIC NEC study. Ann Oncol 2013;24:152-60.
the treatment of pancreatic neuroendocrine tumors. N Engl J Med 32. Dominguez S, Denys A, Madeira I, Hammel P, Vilgrain V, Menu
2011;364:501-13. Y, Bernades P, Ruszniewski P. Hepatic arterial chemoembolization
28. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler with streptozotocin in patients with metastatic digestive endocrine
RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van tumours. Eur J Gastroenterol Hepatol 2000;12:151-7.
Cutsem E, Yao JC; RADIANT-2 Study Group. Everolimus plus
octreotide long-acting repeatable for the treatment of advanced 33. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC,
neuroendocrine tumours associated with carcinoid syndrome McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic
(RADIANT-2): a randomised, placebo-controlled, phase 3 study. arterial embolization and chemoembolization for the treatment of
Lancet 2011;378:2005-12. patients with metastatic neuroendocrine tumors: variables affecting
29. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania response rates and survival. Cancer 2005;104:1590-602.
M, Salazar R, Plöckinger U; Mallorca Consensus Conference 34. Yang TX, Chua TC, Morris DL. Radioembolization and
participants; European Neuroendocrine Tumor Society. ENETS chemoembolization for unresectable neuroendocrine liver metastases
consensus guidelines for the standards of care in neuroendocrine - a systematic review. Surg Oncol 2012;21:299-308.
tumors: chemotherapy in patients with neuroendocrine tumors. 35. Roche A, Girish BV, de Baere T, Ducreux M, Elias D, Laplanche A,
Neuroendocrinology 2009;90:214-9. Boige V, Schlumberger M, Ruffle P, Baudin E. Prognostic factors
30. Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, for chemoembolization in liver metastasis from endocrine tumors.
Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D, Debaere Hepatogastroenterology 2004;51:1751-6.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦ 309